Amphastar Pharmaceuticals, Inc. (AMPH:NASDAQ) closed at $25.14 on October 23, 2026, down 3.46% on the day. The stock trades 14.8% below its 52-week high of $29.52 and 51.0% above its 52-week low of $16.65. Over the past year, it gained 2.5%. Amphastar Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, AMPH closed higher on 132 days (52%). Its best day was November 10, 2025 (+8.70%) and its worst was February 27, 2026 (-23.63%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorol...
Find more stocks like AMPH with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.